Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gastrohep.2014.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Qingchang suppositry induced remission in patients with mild-to-moderate ulcerative proctitis: a multicenter, prospective, randomized, parallel-controlled clinical trial.
J Tradit Chin Med
February 2024
Department of Gastroenterology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Objective: To evaluate the efficacy and safety of Qingchang suppository (, QCS), a preparation of Chinese herbal medicine, in the induction of remission in patients with mild-to-moderate ulcerative proctitis (UP).
Methods: We performed a multicenter, prospective, randomized, parallel-controlled trial to evaluate the efficacy of QCS induction therapy in 140 adult patients with mild-to-moderate UP and TCM syndrome of dampness-heat in large intestine. The patients were randomized to receive QCS (study group) or Salicylazosulfapyridine (SASP) suppository (control group) one piece each time, twice a day, per anum for 12 weeks.
Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
Histopathology
April 2024
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Aims: Ocrelizumab is a humanized anti-CD20-monoclonal antibody that has recently been approved for the treatment of certain types of multiple sclerosis. Isolated case reports of ocrelizumab-associated colitis have been reported in the literature. We present a case series of ocrelizumab-associated intestinal injury with a focus on histopathologic features and report a case of ocrelizumab-associated hepatitis.
View Article and Find Full Text PDFMesalazine-induced esophageal ulcers. A rare adverse effect.
Rev Esp Enferm Dig
May 2024
Aparato Digestivo, Hospital Universitario Son Espases, España.
31-year-old woman. Diagnosis of ulcerative proctitis in February/2022. Calprotectin 1832 μg/g.
View Article and Find Full Text PDFLocal administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis.
JCI Insight
May 2023
Department of Gastroenterology and Hepatology.
BACKGROUNDDue to their immunoregulatory and tissue regenerative features, mesenchymal stromal cells (MSCs) are a promising novel tool for the management of ulcerative proctitis (UP). Here we report on a phase IIa clinical study that evaluated the impact of local MSC therapy on UP.METHODSThirteen refractory UP patients, with an endoscopic Mayo score (EMS) of 2 or 3, were included.
View Article and Find Full Text PDFHeparin-induced thrombocytopenia following Shiga-toxin-associated hemolytic uremic syndrome: a case report.
J Med Case Rep
October 2022
Department of Medicine, Division of Nephrology, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background: Up to 50% of cases of Shiga-toxin-producing Escherichia coli hemolytic uremic syndrome occur in adults, and the clinical presentation is variable. Microbiological analyses must be performed in all patients with thrombotic microangiopathy to identify Shiga-toxin-producing Escherichia coli, even in the absence of diarrhea.
Case Presentation: A 79-year-old Caucasian woman was admitted to hospital because of severe proctitis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!